openPR Logo
Press release

NOACs Pricing, Reimbursement, and Access

08-08-2017 08:39 AM CET | Health & Medicine

Press release from: ReportsWorldwide

ReportsWorldwide has announced the addition of a new report title NOACs Pricing, Reimbursement, and Access to its growing collection of premium market research reports.

A combination of the high cost of novel oral anticoagulants (NOACs) (relative to highly genericized vitamin K antagonists) and the large patient populations these drugs address, has resulted in this class of compounds being a top priority for European payers. The impact of NOACs on European budgets is so great that a UK payer stated that this represented their single largest budgetary concern over the past year. However, in the US, payers were not as concerned with the budgetary impact of the NOACs, citing that this falls outside of their top 20 budgetary concerns. Additionally, most interviewed US payer view NOACs as the new standard of care due to their reduction of serious bleeding events and hence cost saving as compared to vitamin K antagonists.

For a Detailed description and table of contents of this report please click here:

Payers interviewed by Datamonitor Healthcare generally view the marketed NOAC compounds as highly similar, acknowledging that while there are some minor differences in the clinical data of these compounds, the rate of events in their trials is so low that it is hard to attribute these differences to the medications. Moving forward, payers view patients with poor renal function as an area of high unmet need.

Payers interviewed discussed how they would welcome a simple dosing regimen that would not need to be modified for patients with poor renal function; this “one size fits all” dosing regimen would simplify the prescribing of physicians and ensure that all of the patients received the correct dose regardless of their renal function.

However, payers cautioned that it is unlikely that improvements in treatment with respect to efficacy and safety can be achieved given the opposing coagulation and anticoagulation processes in the body. They also stress the importance of delivering game-changing improvements and emphasize that a new agent with the same mechanism of action would be unlikely to capture market share or even be reimbursed unless it targeted specific subpopulations that are currently underserved.

Opinions around the clinical attractiveness of betrixaban (pipeline medication in development for prophylaxis of venous thromboembolism) were split, with some viewing the results from the APEX trial as clinically relevant while others did not feel the medication provided benefit.

To Get Sample Copy of Report please visit @

About is a leading provider of global market intelligence reports and services. With research reports from top publishers, consulting and advisory firms, offers instant online access to a growing database of expert insights on global industries, companies, products, geographies and trends.

Press Contact:
Abigail Crasto
Senior Vice President
101, Arch Street
Boston, MA 02110
Phone +1 (617) 398-4994
Fax +1 (617) 398-4995

This release was published on openPR.

Permanent link to this press release:

Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release NOACs Pricing, Reimbursement, and Access here

News-ID: 658655 • Views: 399

More Releases from ReportsWorldwide

World Deep Brain Stimulation Market Top Segments, Key Players Revenue, Growth Ra …
The World Deep Brain Stimulation Market is estimated to represent a global market of USD 751.8 million by 2017 with growth rate of 18.2%. Deep brain stimulation (DBS) procedure is primarily used for the treatment of neuropsychiatric disorders such as mood disorder, dementia, anxiety and others. The procedure involve the use of neurotransmitter (brain pacemaker) that enables to transmit electric impulses to the specific target of brain cells. Increasing incidence
New report explores the Gene Editing Market : Ushering The Next Breakthrough in …
Boston, MA ReportsWorldwide has announced the addition of a new report title Gene Editing The Next Breakthrough in Regenerative Medicine to its growing collection of premium market research reports. Genome editing is a type of genetic engineering in which DNA is replaced, inserted or deleted in a living organism's ggenome using engineered molecular scissors. Believed to be one of the great biotechnology breakthroughs, gene editing is a powerful tool in pharmaceutical research that
Global In-Building Wireless BTSController-based Small Cells Market Analysis and …
Boston, MA ReportsWorldwide has announced the addition of a new report title Global In-Building Wireless BTSController-based Small Cells Market Analysis and Forecast, 2017-2021 to its growing collection of premium market research reports. This report covers the leading in-building wireless enterprise BTS/controller-based small cells network equipment manufacturers: • CommScope/Airvana • Comba Telecom • Ericsson • Huawei Technologies • Nokia • SpiderCloud • ZTE Corporation This report covers the global market share for 2016 shipments as well as a forecast for 2017-2021. To view a detailed description and Table of

More Releases for NOAC

Novel Oral AntiCoagulants (NOAC) Market 2022 Global Key Country Analysis | Johns …
The Novel Oral AntiCoagulants (NOAC) Market size is projected to reach the highest Compound Annual Growth Rate (CAGR) during the forecast period. The research study also studies market activities like drivers, new possibilities, insight, and obstacles. It brings into core surveys about market definition, market division, and severe examination on the lookout. The Novel Oral AntiCoagulants (NOAC) Market research report also includes stability, futility, new chances, and risks of the
Novel Oral AntiCoagulants (NOAC) Market Size 2022: Johnson & Johnson, Bristol-My …
Novel Oral AntiCoagulants (NOAC) Market research report presents the company profile, product specifications, capacity, production value, and 2022-2028 market shares for each company. This market analysis report is generated with the best and most advanced tools of collecting, recording, estimating and analyzing market data. Qualitative and transparent research studies are performed devotedly to offer an excellent industry analysis report for the niche. To figure out the market landscape, brand awareness,
Novel Oral AntiCoagulants (NOAC) Market 2021 | Detailed Report
The Novel Oral AntiCoagulants (NOAC) market research report delivers accurate data and innovative corporate analysis, helping organizations of all sizes make appropriate decisions. The Novel Oral AntiCoagulants (NOAC) report also incorporates the current and future global market outlook in the emerging and developed markets. Moreover, the report also investigates regions/countries expected to witness the fastest growth rates during the forecast period. The Novel Oral AntiCoagulants (NOAC) research report also provides
Global Novel Oral AntiCoagulants (NOAC) Market 2020 - Johnson & Johnson , Bristo …
Goble Hematopoietic Stem Cells (HSCs) Market 2020, Market Size Value CAGR (USD Million)and revenue ($$$) for the historical period (2016 – 19) and projected years (2020 – 26), SWOT, Industry, Sales, Demand, Analysis, Opportunities and Forecast to 2026 All Cover in This Report Hematopoietic Stem Cells (HSCs) Market study on most trending report Global global Hematopoietic Stem Cells (HSCs) Market 2020 Industry Research Report detailed information on the characterization,
Novel Oral AntiCoagulants (NOAC) Market to Escalate by Types, Applications, Regi …
This report at InForGrowth studies the global market size of Novel Oral AntiCoagulants (NOAC) in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Novel Oral AntiCoagulants (NOAC) in these regions. This research report categorizes the global Novel Oral AntiCoagulants (NOAC) market by players/brands, region, type and application. This report also studies the global market status, competition
Novel Oral AntiCoagulants (NOAC) Market 2018 SWOT Analysis by Players: Johnson & …
The Global Novel Oral AntiCoagulants (NOAC) Market 2018 to 2025 renders deep perception of the key regional market status of the Novel Oral AntiCoagulants (NOAC) Industry on a global level that primarily aims the core regions which comprises of continents like Europe, North America, and Asia and the key countries such as United States, Germany, China and Japan. The report on “Global Novel Oral AntiCoagulants (NOAC) Market” is a professional report